SYMLIN® (pramlintide acetate) injection is an adjunctive treatment for adults with type 1 or type 2 diabetes who have failed to achieve desired glucose control despite optimal insulin therapy.
SYMLIN + insulin may provide your patients with A1C reductions
SYMLIN is the first and only FDA-approved synthetic analog of human amylin, and may help your patients improve their diabetes management.
Amylin demonstrates multiple glycemic effects in the body.
Explore the glucoregulatory partnership of insulin and amylin
Insulin and amylin contribute to glucose homeostasis. Secretion of both may be deficient in patients with diabetes.